Theravance Biopharma Inc. (NASDAQ:TBPH) finished Friday with a subtraction of -$0.05 to close at $9.97, a downside of -0.50 percent. An average of 475,840 shares of common stock have been traded in the last five days. There was a gain of $0.02 in the past week, and it reached a new high 13 times over the past 12 months. The last 20 days have seen an average of 357,175 shares traded, while the 50-day average volume stands at 490,208.
TBPH stock has increased by 1.22% in the last month. The company shares reached their 1-month lowest point of $9.39 on 07/26/23. With the stock rallying to its 52-week high on 04/17/23, shares of the company touched a low of $8.89 and a high of $12.03 in 52 weeks. It has reached a new high 8 times so far this year and lost -11.14% or -$1.25 in price. In spite of this, the price is down -17.12% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
TBPH stock investors should be aware that Theravance Biopharma Inc. (TBPH) stock had its last reported insider trading activity 29 days ago on Jul 14. In this transaction, the insider spent $22,848. SVP, RESEARCH & DEVELOPMENT, GRAHAM RICHARD A, disposed of 2,322 shares at a price of $10.69 on Jun 14. The insider now owns more than $24,822 worth of shares. Prior to that, SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda went on to Sale 1,790 shares at $11.13 each on Jun 08. An amount of $19,923 was transacted.
Valuation Metrics
Theravance Biopharma Inc. (TBPH) stock’s beta is 0.42. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 11.82, the price-to-book (PB) ratio at 1.69.
Financial Health
The quick ratio of Theravance Biopharma Inc. for the three months ended June 29 was 10.00, and the current ratio was 10.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Theravance Biopharma Inc.’s EBITDA margin for the year ending June 29 is -141.26%. Its gross profit as reported stood at $51.35 million compared to revenue of $51.35 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Theravance Biopharma Inc.’s return on assets was 154.30%.
Earnings Surprise
For the three-month period that ended June 29, Theravance Biopharma Inc. had $61.86 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$15.65 million in the quarter, while revenues were grew 47.67%. The analyst consensus anticipated Theravance Biopharma Inc.’s latest quarter earnings to come in at -$0.21 per share, but it turned out to be -$0.28, a -33.30% surprise. For the quarter, EBITDA amounted to -$15.98 million. Shareholders own equity worth $52.81 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Theravance Biopharma Inc. (TBPH) price momentum. RSI 9-day as of the close on 11 August was 53.38%, suggesting the stock is Neutral, with historical volatility in this time frame at 31.67%.
As of today, TBPH’s price is $9.95 +0.20% or $0.02 from its 5-day moving average. TBPH is currently trading +1.84% higher than its 20-day SMA and -4.50% lower than its 100-day SMA. However, the stock’s current price level is -10.82% below the SMA50 and -0.30% below the SMA200.
The stochastic %K and %D were 69.46% and 64.35%, respectively, and the average true range (ATR) was 0.30. With the 14-day stochastic at 58.59% and the average true range at 0.28, the RSI (14) stands at 50.34%. The stock has reached 0.15 on the 9-day MACD Oscillator while the 14-day reading was at 0.23.
Analyst Ratings
SVB Leerink launched coverage on Theravance Biopharma Inc. (NASDAQ: TBPH) in its analyst report released on May 23, 2022. The firm assigned the stock an Outperform rating. The consensus rating for Theravance Biopharma Inc. (TBPH) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TBPH, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is TBPH’s price target for the next 12 months?
Analysts predict a range of price targets between $9.00 and $20.00, with a median target of $14.00. Taking a look at these predictions, the average price target given by analysts for Theravance Biopharma Inc. (TBPH) stock is $14.25.
